YaoGeJu

Company directoryChina company filings

Guilin Hwasun Pharmaceutical Co., Ltd.

As of 18 November 2026, for the company name Guilin Hwasun Pharmaceutical Co., Ltd. as recorded, the chemical-drug catalogue lists 10 active records with this name as holder; 17 active API registrations list this name as first registered company.

Check drug filings and source records for this company-name string.

Listed by the company name as recorded in the source, without merging affiliated entities.

Page reference

CDE data as of
2026/11/18
Matching scope
Loaded public-source records only

These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/18.

Drug filings

25 acceptance records as first applicant, grouped into 16 source drug names. Source data as of 2026/11/18.

This source was last successfully updated at 2026/11/18; current coverage may be incomplete.

Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.

Emedastine Difumarate Sustained-release Capsules 2 records · Latest accepted 2026/06/18

Generic · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2601452Generic2026/06/18Guilin Hwasun Pharmaceutical Co., Ltd.CDE ↗
CYHS2601451Generic2026/06/18Guilin Hwasun Pharmaceutical Co., Ltd.CDE ↗
腺苷钴胺胶囊 · No verified English name 2 records · Latest accepted 2026/06/10

Supplement · 1Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2601084Supplement2026/06/10Guilin Hwasun Pharmaceutical Co., Ltd.CDE ↗
CYHS2401296Generic2024/04/29Guilin Hwasun Pharmaceutical Co., Ltd.CDE ↗
Esomeprazole Magnesium Enteric-Coated Capsules 2 records · Latest accepted 2026/04/22

Generic · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2600920Generic2026/04/22Guilin Hwasun Pharmaceutical Co., Ltd.CDE ↗
CYHS2600919Generic2026/04/22Guilin Hwasun Pharmaceutical Co., Ltd.CDE ↗
Fexofenadine Hydrochloride Oral Suspension 1 records · Latest accepted 2026/02/27

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2600563Generic2026/02/27Guilin Hwasun Pharmaceutical Co., Ltd.CDE ↗
Benidipine Hydrochloride Tablets 1 records · Latest accepted 2025/10/17

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2503722Generic2025/10/17Guilin Hwasun Pharmaceutical Co., Ltd.CDE ↗
Candesartan Cilexetil and Hydrochlorothiazide Tablets 1 records · Latest accepted 2025/04/30

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2501617Generic2025/04/30Guilin Hwasun Pharmaceutical Co., Ltd.CDE ↗
Lansoprazole Enteric Capsules 2 records · Latest accepted 2025/03/14

Supplement · 1Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2500525Supplement2025/03/14Guilin Hwasun Pharmaceutical Co., Ltd.CDE ↗
CYHS2301600Generic2023/06/12Guilin Hwasun Pharmaceutical Co., Ltd.CDE ↗
盐酸非索非那定干混悬剂 · No verified English name 2 records · Latest accepted 2025/01/15

Generic · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2500300Generic2025/01/15Guilin Hwasun Pharmaceutical Co., Ltd.CDE ↗
CYHS2500298Generic2025/01/15Guilin Hwasun Pharmaceutical Co., Ltd.CDE ↗
Perindopril Arginine and Amlodipine Besylate Tablets(III) 1 records · Latest accepted 2024/09/25

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2403160Generic2024/09/25Guilin Hwasun Pharmaceutical Co., Ltd.CDE ↗
Terbinafine Hydrochloride Cream 1 records · Latest accepted 2024/09/13

Supplement · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2401458Supplement2024/09/13Guilin Hwasun Pharmaceutical Co., Ltd.CDE ↗
Metoprolol Succinate Extended-release Capsules 2 records · Latest accepted 2024/08/08

Generic · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2402530Generic2024/08/08Guilin Hwasun Pharmaceutical Co., Ltd.CDE ↗
CYHS2402529Generic2024/08/08Guilin Hwasun Pharmaceutical Co., Ltd.CDE ↗
Acetylcysteine Granules 4 records · Latest accepted 2023/07/12

Supplement · 3Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2301557Supplement2023/07/12Guilin Hwasun Pharmaceutical Co., Ltd.CDE ↗
CYHB2301317Supplement2023/06/12Guilin Hwasun Pharmaceutical Co., Ltd.CDE ↗
CYHB2300306Supplement2023/02/16Guilin Hwasun Pharmaceutical Co., Ltd.CDE ↗
CYHS2101420Generic2021/07/08Guilin Hwasun Pharmaceutical Co., Ltd.CDE ↗
磷霉素氨丁三醇颗粒 · No verified English name 1 records · Latest accepted 2023/04/27

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2301185Generic2023/04/27Guilin Hwasun Pharmaceutical Co., Ltd.CDE ↗
Fluvoxamine Maleate Tablets 1 records · Latest accepted 2022/09/29

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2201633Generic2022/09/29Guilin Hwasun Pharmaceutical Co., Ltd.CDE ↗
Omeprazole Enteric Capsules 1 records · Latest accepted 2021/07/16

Supplement · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2150739Supplement2021/07/16Guilin Hwasun Pharmaceutical Co., Ltd.CDE ↗
Valsartan Capsules 1 records · Latest accepted 2021/02/22

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2100218Generic2021/02/22Guilin Hwasun Pharmaceutical Co., Ltd.CDE ↗

Changes in the last 90 days

2 events from 2026/08/22 to 2026/11/19. CDE data as of 2026/11/18; NMPA data as of 2026/11/19.

This source was last successfully updated at 2026/11/18; current coverage may be incomplete.

Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.

Marketing application approved: 1 applicationNo longer listed under review: 1 application

  1. 2026/11/10Marketing application approved

    Candesartan Cilexetil and Hydrochlorothiazide Tablets(II)

    CYHS2501617 · 国药准字H20266578

    Fact date: 2026/11/10 · Publication date: 2026/11/13 · Date added to this site: 2026/11/14

    View source · Table row 64 ↗
  2. 2026/10/29No longer listed under review

    Candesartan Cilexetil and Hydrochlorothiazide Tablets

    CYHS2501617

    Fact date: 2026/10/29 · Date added to this site: 2026/10/29

    Accepted: 2025/04/30

    no longer on the CDE under-review list as of the data cut-off; the review / approval outcome is to be checked

    View source ↗

Under review

7 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/18.

This source was last successfully updated at 2026/11/18; current coverage may be incomplete.

Under review
Drug Acceptance numberApplication typeAcceptedCompany / applicantView source
Emedastine Difumarate Sustained-release Capsules CYHS2601452Generic2026/06/18Guilin Hwasun Pharmaceutical Co., Ltd.CDE ↗
Emedastine Difumarate Sustained-release Capsules CYHS2601451Generic2026/06/18Guilin Hwasun Pharmaceutical Co., Ltd.CDE ↗
腺苷钴胺胶囊 · No verified English name CYHB2601084Supplement2026/06/10Guilin Hwasun Pharmaceutical Co., Ltd.CDE ↗
Esomeprazole Magnesium Enteric-Coated Capsules CYHS2600920Generic2026/04/22Guilin Hwasun Pharmaceutical Co., Ltd.CDE ↗
Esomeprazole Magnesium Enteric-Coated Capsules CYHS2600919Generic2026/04/22Guilin Hwasun Pharmaceutical Co., Ltd.CDE ↗
Fexofenadine Hydrochloride Oral Suspension CYHS2600563Generic2026/02/27Guilin Hwasun Pharmaceutical Co., Ltd.CDE ↗
Benidipine Hydrochloride Tablets CYHS2503722Generic2025/10/17Guilin Hwasun Pharmaceutical Co., Ltd.CDE ↗

Catalogue holder records

10 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/18. Manufacturer-only records are excluded.

DrugMarketing authorization holderManufacturerApproval numberApprovedCatalogue category (source text)View source
Perindopril Arginine and Amlodipine Besylate Tablets(III)Guilin Hwasun Pharmaceutical Co., Ltd.Guilin Hwasun Pharmaceutical Co., Ltd.国药准字H202633482026/02/02Generic approved under the new chemical-drug registration classificationCDE ↗
Metoprolol Succinate Extended-release CapsulesGuilin Hwasun Pharmaceutical Co., Ltd.Guilin Hwasun Pharmaceutical Co., Ltd.国药准字H202562692025/12/16Generic approved under the new chemical-drug registration classificationCDE ↗
Metoprolol Succinate Extended-release CapsulesGuilin Hwasun Pharmaceutical Co., Ltd.Guilin Hwasun Pharmaceutical Co., Ltd.国药准字H202562702025/12/16Generic approved under the new chemical-drug registration classificationCDE ↗
腺苷钴胺胶囊 · No verified English nameGuilin Hwasun Pharmaceutical Co., Ltd.Guilin Hwasun Pharmaceutical Co., Ltd.国药准字H202551852025/08/26Other drugCDE ↗
Lansoprazole Enteric CapsulesGuilin Hwasun Pharmaceutical Co., Ltd.Guilin Hwasun Pharmaceutical Co., Ltd.国药准字H202449092024/09/19Generic approved under the new chemical-drug registration classificationCDE ↗
Fluvoxamine Maleate TabletsGuilin Hwasun Pharmaceutical Co., Ltd.Guilin Hwasun Pharmaceutical Co., Ltd.国药准字H202435382024/04/17Generic approved under the new chemical-drug registration classificationCDE ↗
Acetylcysteine GranulesGuilin Hwasun Pharmaceutical Co., Ltd.Guilin Hwasun Pharmaceutical Co., Ltd.国药准字H202238422022/11/15Generic approved under the new chemical-drug registration classificationCDE ↗
Omeprazole Enteric CapsulesGuilin Hwasun Pharmaceutical Co., Ltd.Guilin Hwasun Pharmaceutical Co., Ltd.国药准字H201432042022/06/21Drug that passed quality-and-efficacy consistency evaluationCDE ↗
Valsartan CapsulesGuilin Hwasun Pharmaceutical Co., Ltd.Guilin Hwasun Pharmaceutical Co., Ltd.国药准字H202232402022/04/19Generic approved under the new chemical-drug registration classificationCDE ↗
Venlafaxine Hydrochloride Sustained-Release CapsulesGuilin Hwasun Pharmaceutical Co., Ltd.Guilin Hwasun Pharmaceutical Co., Ltd.国药准字H202230352022/01/30Generic approved under the new chemical-drug registration classificationCDE ↗

Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.

API registrations

17 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/18.

NameCompany / applicantRegistration numberStatusSource update dateView source
右兰索拉唑 · No verified English nameGuilin Hwasun Pharmaceutical Co., Ltd.Y20260000845I2026/10/21CDE ↗
盐酸贝尼地平 · No verified English nameGuilin Hwasun Pharmaceutical Co., Ltd.Y20250001017I2025/09/24CDE ↗
雷贝拉唑钠 · No verified English nameGuilin Hwasun Pharmaceutical Co., Ltd.Y20240000625A2025/12/18CDE ↗
琥珀酸美托洛尔 · No verified English nameGuilin Hwasun Pharmaceutical Co., Ltd.Y20230000348A2026/03/12CDE ↗
艾司奥美拉唑镁 · No verified English nameGuilin Hwasun Pharmaceutical Co., Ltd.Y20200001423A2026/06/02CDE ↗
盐酸文拉法辛 · No verified English nameGuilin Hwasun Pharmaceutical Co., Ltd.Y20190009845A2024/08/23CDE ↗
奥美拉唑钠 · No verified English nameGuilin Hwasun Pharmaceutical Co., Ltd.Y20190009696A2024/09/27CDE ↗
兰索拉唑 · No verified English nameGuilin Hwasun Pharmaceutical Co., Ltd.Y20190008644A2024/09/21CDE ↗
奥美拉唑 · No verified English nameGuilin Hwasun Pharmaceutical Co., Ltd.Y20190008084A2024/09/21CDE ↗
泮托拉唑钠 · No verified English nameGuilin Hwasun Pharmaceutical Co., Ltd.Y20190006133A2024/09/21CDE ↗
酮康唑 · No verified English nameGuilin Hwasun Pharmaceutical Co., Ltd.Y20190006132A2025/01/01CDE ↗
磷霉素氨丁三醇 · No verified English nameGuilin Hwasun Pharmaceutical Co., Ltd.Y20190005284A2024/09/21CDE ↗
胶体果胶铋 · No verified English nameGuilin Hwasun Pharmaceutical Co., Ltd.Y20190001385A2025/01/01CDE ↗
奥美拉唑钠 · No verified English nameGuilin Hwasun Pharmaceutical Co., Ltd.Y20190000169I2019/04/01CDE ↗
兰索拉唑 · No verified English nameGuilin Hwasun Pharmaceutical Co., Ltd.Y20180001274A2025/12/31CDE ↗
盐酸文拉法辛 · No verified English nameGuilin Hwasun Pharmaceutical Co., Ltd.Y20180000005I2019/01/14CDE ↗
马来酸氟伏沙明 · No verified English nameGuilin Hwasun Pharmaceutical Co., Ltd.Y20170001375A2026/06/02CDE ↗

Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.

Co-applicant records

0 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/18.

This source was last successfully updated at 2026/11/18; current coverage may be incomplete.

Co-applicant records
Drug Acceptance numberApplication typeAcceptedCompany / applicantView source
No matching records were found in the currently loaded source data; coverage dates are listed below.

How current is each source?

CDE acceptances and review
Last successful update: 2026/11/18 · Current coverage may be incomplete
Chemical-drug catalogue
Last successful update: 2026/11/18
API registrations
Last successful update: 2026/11/18
NMPA drug delivery notices
Last successful update: 2026/11/19

Loaded notices dated 2026-11-05 to 2026-11-19; 0 notices not yet loaded. Covers loaded notices only, not a complete historical approval database.

Listed by the company name as recorded in the source, without merging affiliated entities.

This page summarizes loaded records only. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.

Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.

Drugs with a verified official English name use that name only. Other drug names retain the Chinese source name marked No verified English name; names with a Chinese public page link to that page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized; Chinese company names are not displayed. Marked unverified drug names and original statutory reference numbers may appear in Chinese.

Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.